Skip to main content

Table 2 Comparison of the changes of liver and kidney function in patients with different Child–Pugh scores in the 1 week group (M (P25–P75))

From: Efficacy and safety of caspofungin for patients with hepatic insufficiency

Group

Time

albumin

g/L

ALT

U/L

AST

U/L

ALP

U/L

GGT

U/L

TBIL

U/L

Scr

mmol/L

eGFR

ml/min

A

D0

D1

D7

X2

P

33.7 (29–37)

33.3 (30–35)

31.4 (29–33)

5.79

0.06

28.0 (13–60)

24.5 (12–71)

21.5 (12–41)

2.80

0.25

20.0 (16–40)

20.5 (13–38)

22.5 (13–40.)

3.98

0.14

85.0 (72–133)

85.5 (60–124)

80.0 (63–108)

9.41

0.01

68.0 (31–191)

67.0 (29–172)*

52.0 (22–100)*#

14.00

0.01

9.0 (5–13)

8.8 (5–12)

7.9 (6–11)

1.17

0.56

62.9 (53–85)

60.9 (48–86)

61.0 (45–71)

6.39

0.04

78.8 (52–96)

87.7 (60–107)

94.9 (63–120)

5.43

0.06

B

D0

D1

D7

X2

P

30.0 (28–32)

29.3 (26–32)

29.9 (28–32)

1.69

0.43

37.5 (16–80)

36.0 (12–71)

27.5 (14–59)

1.922

0.382

48.5 (27–84)

45.5 (23–99)

60.1 (25–86)

0.75

0.69

115.5 (68–147)

114.5 (70–154)

112.0 (90–209)

0.14

0.93

83.0 (29–165)

88.0 (34–153)

92.5 (37–143)

2.02

0.37

21.1 (10–42)

13.8 (8–40)

18.2 (8–36)

3.32

0.21

68.7 (56–100)

77.0 (50–106)

81.8 (58–112)

0.39

0.82

81.6 (46–106)

79.4 (45`104)

77.4 (37–98)

0.2

0.91

C

D0

D1

D7

X2

P

30.6 (25–34)

30.0 (27–35)

31.0 (27–34)

0.22

0.89

21.0 (16–32)

22.0 (14–32)

17.0 (10–41)

0.456

0.796

48.0 (28–85)

44.0 (30–65)

55.0 (33–117)

2.63

0.27

88.0 (71–171)

77.0 (67–157)

86.0 (68–153)

5.52

0.06

37.0 (25–85)

37.0 (24–60)

46.0 (23–66)

7.18

0.03

163.0 (51–324)

156.0 (67–276)

162.0 (62–308)

0.65

0.72

89.0 (54–146)

83.4 (62–168)

79.9 (64–142)

0.78

0.68

69.6 (30–91)

69.7 (32–97)

65.0 (36–86)

1.00

0.61

  1. *Bonferroni's correction, compared with D0, the difference was statistically significant
  2. #Bonferroni's correction, compared with D1, the difference was statistically significant